Antibody-drug conjugate · Cytotoxic, directed at PTK7 (protein tyrosine kinase 7) (PTK7) · developed by ELI LILLY &
LY4175408 is an antibody-drug conjugate in which a fully human, Fc-silenced IgG1 antibody binds PTK7 on tumor cells and delivers the topoisomerase I inhibitor exatecan after internalization and linker cleavage. It is being studied in non-small cell lung cancer, small cell lung cancer, endometrial cancer and triple negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07046923 | Phase 1 | Carcinoma, Non-Small-Cell Lung | Active not recruiting | LLY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Carcinoma, Non-Small-Cell LungEndometrial NeoplasmsNeoplasm MetastasisSmall Cell Lung CarcinomaTriple Negative Breast Cancer
See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LLY catalysts and pipeline →